Navigation Links
Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting

breast cancer clinical trial in the first half of 2007 and that a patient remains on study in the ovarian trial.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is ongoing.

The NCI has sponsored six additional Phase II clinical trials, one evaluating the potential efficacy of ispinesib in the second-line treatment of patients with colorectal cancer, one in the first-line treatment of patients with hepatocellular cancer, one in the first-line treatment of patients with melanoma, one in the first- or second-line treatment of patients with head and neck cancers, one in the second-line treatment of patients with hormone- refractory prostate cancer, and one in the second-line treatment of patients with renal cell cancer. Enrollment has been closed for all of these trials; patients remain on treatment in the renal cell cancer trial. Data are expected from the hepatocellular cancer, the prostate cancer, the melanoma, and the renal cell cancer trials in 2007. Data from other clinical trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with acute leukemia, chronic mye
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... Nov. 26, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has issued a ... (NDA) for AVP-825. AVP-825 is an investigational drug-device ... intranasally utilizing a novel Breath Powered delivery technology. ... and consistent with the preliminary feedback announced on ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Inc. announced an agreement with the United States Department of ... prescription medication for patients with heart failure. ... plea to a single misdemeanor violation of the Food, Drug ... fine. Scios acknowledges that NATRECOR® was misbranded and ...
... Oct. 5, 2011 SV Life Sciences ("SVLS") today announced the ... joins SVLS with more than 26 years of experience in ... excited to welcome Dr. Dreismann to SVLS," said Lutz Giebel, ... and focus on investments in the diagnostics space. We believe ...
Cached Medicine Technology:SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner 2
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
(Date:11/28/2014)... November 28, 2014 An inventor from Flint, ... to day. "I got this idea while lying in a ... bathroom," he said. , The Bed Buddy provides a more ... to the bathroom. It eliminates the need to leave the ... comfort and dignity. Easy to use and producible in design ...
(Date:11/28/2014)... 28, 2014 talklocal ( http://www.talklocal.com ... the right service professionals by phone in about 90 seconds. ... least two tornadoes were reported to have touched down just ... was reported following the tornadoes, Denver residents now know all ... Having TalkLocal is like having local pros in over 50 ...
(Date:11/28/2014)... November 28, 2014 This report ... market along with the definite portrayal of the ... point depiction of various variables driving the development ... difficulties blocking the development of the business. ... , According to the report "Worldwide Dental ...
(Date:11/27/2014)... (PRWEB) November 28, 2014 One ... implant dentistry. The market for implant dentistry comprises ... tools/instruments. The global market for dental care is ... equipments. The dental equipment segment is composed of ... of contents at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The ...
Breaking Medicine News(10 mins):Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3
... to be more effective than placebos in treating rapid ... study , which included 38 non-schizophrenic, non-bipolar women with ... 51 was conducted by researchers from various universities in ... shift, impulsivity and aggression when given fluvoxamine or a ...
... a national survey of more than 149,000 Americans including 23,000 ... 25% of adults with disabilities, compared to 16 per cent ... defined as having a Body Mass Index greater than 32. ... mobility difficulties and those who had not received exercise counselling ...
... on both mice and humans are showing why some people absorb ... if you eat a fatty meal or snack - a fried ... you absorb is strongly influenced by your genes. Experts know that ... fat diet is bad for you. But little has been discovered ...
... in there study are trying to observe why surgery ... ongoing. It's long been known that some older people develop ... - a condition known as Post Operative Cognitive Dysfunction (POCD).Often ... same' as they were before surgery. It was assumed, at ...
... observed that a drug already being used to treat ... male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, which has ... work// as a male contraceptive because it affects the ... tested their theory in an animal study involving mice. ...
... the eye has prevented and stopped autoimmune eye disease in ... treatments for other// autoimmune diseases such as multiple sclerosis and ... Institute in Boston found the factor alpha-MSH can be harnessed ... prevent the onset of and stop the progression of uveitis ...
Cached Medicine News:
Hibbs Retractor with sharp teeth. Used for deep soft tissue retraction....
A general purpose instrument for use around the femur and acetabulum....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
The double action wire cutter has both side and end cutting capabilities....
Medicine Products: